Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Receivables (2016 - 2021)

Viridian Therapeutics, Inc.\DE (VRDN) has 8 years of Receivables data on record, last reported at $1.5 million in Q3 2021.

  • For Q3 2021, Receivables rose 2494.74% year-over-year to $1.5 million; the TTM value through Sep 2021 reached $1.5 million, up 2494.74%, while the annual FY2019 figure was $108000.0, 350.0% up from the prior year.
  • Receivables reached $1.5 million in Q3 2021 per VRDN's latest filing, up from $57000.0 in the prior quarter.
  • Across five years, Receivables topped out at $5.8 million in Q1 2018 and bottomed at $4000.0 in Q1 2020.
  • Average Receivables over 5 years is $1.2 million, with a median of $979000.0 recorded in 2019.
  • Peak YoY movement for Receivables: tumbled 99.9% in 2019, then surged 2494.74% in 2021.
  • A 5-year view of Receivables shows it stood at $2.6 million in 2017, then crashed by 99.06% to $24000.0 in 2018, then surged by 3979.17% to $979000.0 in 2019, then tumbled by 94.18% to $57000.0 in 2020, then soared by 2494.74% to $1.5 million in 2021.
  • Per Business Quant database, its latest 3 readings for Receivables were $1.5 million in Q3 2021, $57000.0 in Q3 2020, and $248000.0 in Q2 2020.